https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Progesterone+AND+Gel+AND+For+AND+Vaginal+AND+Use+AND+Only&limit=1&skip=0
Page 0 of 3
        "generic_name": [
          "PROGESTERONE"
        "brand_name": [
          "Crinone"
 
      "drug_interactions": [
        "Drug Interactions No drug interactions have been assessed with Crinone(R)."
      "adverse_reactions": [
        "ADVERSE REACTIONS Assisted Reproductive Technology In a study of 61 women with ovarian failure undergoing a donor oocyte transfer procedure receiving Crinone(R) 8% twice daily, treatment-emergent adverse events occurring in 5% or more of the women are shown in Table 3. TABLE 3 Treatment-Emergent Adverse Events in >=5% of Women Receiving Crinone(R) 8% Twice Daily Study COL1620-007US (n=61) Body as a Whole Bloating 7% Cramps NOS 15% Pain 8% Central and Peripheral Nervous System Dizziness 5% Headache 13% Gastro-Intestinal System Nausea 7% Reproductive, Female Breast Pain 13% Moniliasis Genital 5% Vaginal Discharge 7% Skin and Appendages Pruritus Genital 5% In a second clinical study of 139 women using Crinone(R) 8% once daily for luteal phase support while undergoing an in vitro fertilization procedure, treatment-emergent adverse events reported in >=5% of the women are shown in Table 4. TABLE 4 Treatment-Emergent Adverse Events in >=5% of Women Receiving Crinone(R) 8% Once Daily Study COL1620-F01 (n=139) Body as a Whole Abdominal Pain 12% Perineal Pain Female 17% Central and Peripheral Nervous System Headache 17% Gastro-Intestinal System Constipation 27% Diarrhea 8% Nausea 22% Vomiting 5% Musculo-Skeletal System Arthralgia 8% Psychiatric Depression 11% Libido Decreased 10% Nervousness 16% Somnolence 27% Reproductive, Female Breast Enlargement 40% Dyspareunia 6% Urinary System Nocturia 13% Secondary Amenorrhea In three studies, 127 women with secondary amenorrhea received estrogen replacement therapy and Crinone(R) 4% or 8% every other day for six doses. Treatment emergent adverse events during estrogen and Crinone(R) treatment that occurred in 5% or more of women are shown in Table 5. TABLE 5 Treatment-Emergent Adverse Events in >=5% of Women Receiving Estrogen Treatment and Crinone(R) Every Other Day Studies COL1620-004US, COL1620-005US, COL1620-009US Estrogen + Crinone(R) 4% n=62 Estrogen + Crinone(R) 8% n=65 Body as a Whole Abdominal Pain 3 (5%) 6 (9%) Appetite Increased 3 (5%) 5 (8%) Bloating 8 (13%) 8 (12%) Cramps NOS 12 (19%) 17 (26%) Fatigue 13 (21%) 14 (22%) Central and Peripheral Nervous System Headache 12 (19%) 10 (15%) Gastro-Intestinal System Nausea 5 (8%) 4 (6%) Musculo-Skeletal System Back Pain 5 (8%) 2 (3%) Myalgia 5(8%) 0(0%) Psychiatric Depression 12 (19%) 10 (15%) Emotional Lability 14 (23%) 14 (22%) Sleep Disorder 11 (18%) 12 (18%) Reproductive, Female Vaginal Discharge 7 (11%) 2 (3%) Resistance Mechanism Upper Respiratory Tract Infection 3 (5%) 5 (8%) Skin and Appendages Pruitis genital 1 (2%) 4 (6%) Additional adverse events reported in women at a frequency <5% in Crinone(R) ART and secondary amenorrhea studies and not listed in the tables above include: Autonomic Nervous System-mouth dry, sweating increased Body as a Whole-abnormal crying, allergic reaction, allergy, appetite decreased, asthenia, edema, face edema, fever, hot flushes, influenza-like symptoms, water retention, xerophthalmia Cardiovascular, General-syncope Central and Peripheral Nervous System-migraine, tremor Gastro-Intestinal-dyspepsia, eructation, flatulence, gastritis, toothache Metabolic and Nutritional-thirst Musculo-Skeletal System-cramps legs, leg pain, skeletal pain Neoplasm-benign cyst Platelet, Bleeding & Clotting-purpura Psychiatric-aggressive reactions, forgetfulness, insomnia Red Blood Cell-anemia Reproductive, Female-dysmenorrhea, premenstrual tension, vaginal dryness Resistance Mechanism-infection, pharyngitis, sinusitis, urinary tract infection Respiratory System-asthma, dyspnea, hyperventilation, rhinitis Skin and Appendages-acne, pruritis, rash, seborrhea, skin discoloration, skin disorder, urticaria Urinary System-cystitis, dysuria, micturition frequency Vision Disorders-conjunctivitis"
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Progesterone+AND+Gel+AND+For+AND+Vaginal+AND+Use+AND+Only&limit=1&skip=1
Page 1 of 3
        "generic_name": [
          "PROGESTERONE"
        "brand_name": [
          "Crinone"
 
      "drug_interactions": [
        "Drug Interactions No drug interactions have been assessed with Crinone."
      "adverse_reactions": [
        "ADVERSE REACTIONS Assisted Reproductive Technology In a study of 61 women with ovarian failure undergoing a donor oocyte transfer procedure receiving Crinone 8% twice daily, treatment-emergent adverse events occurring in 5% or more of the women are shown in Table 3. TABLE 3 Treatment-Emergent Adverse Events in >= 5% of Women Receiving Crinone 8% Twice Daily Study COL1620-007US (n = 61) Body as a Whole Bloating 7% Cramps NOS 15% Pain 8% Central and Peripheral Nervous System Dizziness 5% Headache 13% Gastro-Intestinal System Nausea 7% Reproductive, Female Breast Pain 13% Moniliasis Genital 5% Vaginal Discharge 7% Skin and Appendages Pruritus Genital 5% In a second clinical study of 139 women using Crinone 8% once daily for luteal phase support while undergoing an in vitro fertilization procedure, treatment-emergent adverse events reported in >= 5% of the women are shown in Table 4. TABLE 4 Treatment-Emergent Adverse Events in >= 5% of Women Receiving Crinone 8% Once Daily Study COL1620-F01 (n = 139) Body as a Whole Abdominal Pain 12% Perineal Pain Female 17% Central and Peripheral Nervous System Headache 17% Gastro-Intestinal System Constipation 27% Diarrhea 8% Nausea 22% Vomiting 5% Musculo-Skeletal System Arthralgia 8% Psychiatric Depression 11% Libido Decreased 10% Nervousness 16% Somnolence 27% Reproductive, Female Breast Enlargement 40% Dyspareunia 6% Urinary System Nocturia 13% Secondary Amenorrhea In three studies, 127 women with secondary amenorrhea received estrogen replacement therapy and Crinone 4% or 8% every other day for six doses. Treatment-emergent adverse events during estrogen and Crinone treatment that occurred in 5% or more of women are shown in Table 5. TABLE 5 Treatment-Emergent Adverse Events in >= 5% of Women Receiving Estrogen Treatment and Crinone Every Other Day Studies COL1620-004US, COL1620-005US, COL1620-009US Estrogen + Crinone 4% n = 62 Estrogen + Crinone 8% n = 65 Body as a Whole Abdominal Pain 3 (5%) 6 (9%) Appetite Increased 3 (5%) 5 (8%) Bloating 8 (13%) 8 (12%) Cramps NOS 12 (19%) 17 (26%) Fatigue 13 (21%) 14 (22%) Central and Peripheral Nervous System Headache 12 (19%) 10 (15%) Gastro-Intestinal System Nausea 5 (8%) 4 (6%) Musculo-Skeletal System Back Pain 5 (8%) 2 (3%) Myalgia 5 (8%) 0 (0%) Psychiatric Depression 12 (19%) 10 (15%) Emotional Lability 14 (23%) 14 (22%) Sleep Disorder 11 (18%) 12 (18%) Reproductive, Female Vaginal Discharge 7 (11%) 2 (3%) Resistance Mechanism Upper Respiratory Tract Infection 3 (5%) 5 (8%) Skin and Appendages Pruritus Genital 1 (2%) 4 (6%)"
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Progesterone+AND+Gel+AND+For+AND+Vaginal+AND+Use+AND+Only&limit=1&skip=2
Page 2 of 3
        "generic_name": [
          "PROGESTERONE"
        "brand_name": [
          "Prochieve"
 
      "drug_interactions": [
        "Drug Interactions No drug interactions have been assessed with Prochieve(R)."
      "adverse_reactions": [
        "ADVERSE REACTIONS Assisted Reproductive Technology In a study of 61 women with ovarian failure undergoing a donor oocyte transfer procedure receiving Prochieve(R) 8% twice daily, treatment-emergent adverse events occurring in 5% or more of the women are shown in Table 3. TABLE 3 Treatment-Emergent Adverse Events in >=5% of Women Receiving Prochieve(R) 8% Twice Daily Study COL1620-007US (n=61) Body as a Whole Bloating 7% Cramps NOS 15% Pain 8% Central and Peripheral Nervous System Dizziness 5% Headache 13% Gastro-Intestinal System Nausea 7% Reproductive, Female Breast Pain 13% Moniliasis Genital 5% Vaginal Discharge 7% Skin and Appendages Pruritus Genital 5% In a second clinical study of 139 women using Prochieve(R) 8% once daily for luteal phase support while undergoing an in vitro fertilization procedure, treatment-emergent adverse events reported in >=5% of the women are shown in Table 4. TABLE 4 Treatment-Emergent Adverse Events in >=5% of Women Receiving Prochieve(R) 8% Once Daily Study COL1620-F01 (n=139) Body as a Whole Abdominal Pain 12% Perineal Pain Female 17% Central and Peripheral Nervous System Headache 17% Gastro-Intestinal System Constipation 27% Diarrhea 8% Nausea 22% Vomiting 5% Musculo-Skeletal System Arthralgia 8% Psychiatric Depression 11% Libido Decreased 10% Nervousness 16% Somnolence 27% Reproductive, Female Breast Enlargement 40% Dyspareunia 6% Urinary System Nocturia 13% Secondary Amenorrhea In three studies, 127 women with secondary amenorrhea received estrogen replacement therapy and Prochieve(R) 4% or 8% every other day for six doses. Treatment emergent adverse events during estrogen and Prochieve(R) treatment that occurred in 5% or more of women are shown in Table 5. TABLE 5 Treatment-Emergent Adverse Events in >=5% of Women Receiving Estrogen Treatment and Prochieve(R) Every Other Day Studies COL1620-004US, COL1620-005US, COL1620-009US Estrogen + Prochieve(R) 4% n=62 Estrogen + Prochieve(R) 8% n=65 Body as a Whole Abdominal Pain 3 (5%) 6 (9%) Appetite Increased 3 (5%) 5 (8%) Bloating 8 (13%) 8 (12%) Cramps NOS 12 (19%) 17 (26%) Fatigue 13 (21%) 14 (22%) Central and Peripheral Nervous System Headache 12 (19%) 10 (15%) Gastro-Intestinal System Nausea 5 (8%) 4 (6%) Musculo-Skeletal System Back Pain 5 (8%) 2 (3%) Myalgia 5.(8%) 0 (0%) Psychiatric Depression 12 (19%) 10 (15%) Emotional Lability 14 (23%) 14 (22%) Sleep Disorder 11 (18%) 12 (18%) Reproductive, Female Vaginal Discharge 7 (11%) 2 (3%) Resistance Mechanism Upper Respiratory Tract Infection 3 (5%) 5 (8%) Skin and Appendages Pruitis genital 1 (2%) 4 (6%) Additional adverse events reported in women at a frequency <5% in Prochieve(R) ART and secondary amenorrhea studies and not listed in the tables above include: Autonomic Nervous System-mouth dry, sweating increased Body as a Whole-abnormal crying, allergic reaction, allergy, appetite decreased, asthenia, edema, face edema, fever, hot flushes, influenza-like symptoms, water retention, xerophthalmia Cardiovascular, General-syncope Central and Peripheral Nervous System-migraine, tremor Gastro-Intestinal-dyspepsia, eructation, flatulence, gastritis, toothache Metabolic and Nutritional-thirst Musculo-Skeletal System-cramps legs, leg pain, skeletal pain Neoplasm-benign cyst Platelet, Bleeding & Clotting-purpura Psychiatric-aggressive reactions, forgetfulness, insomnia Red Blood Cell-anemia Reproductive, Female-dysmenorrhea, premenstrual tension, vaginal dryness Resistance Mechanism-infection, pharyngitis, sinusitis, urinary tract infection Respiratory System-asthma, dyspnea, hyperventilation, rhinitis Skin and Appendages-acne, pruritis, rash, seborrhea, skin discoloration, skin disorder, urticaria Urinary System-cystitis, dysuria, micturition frequency Vision Disorders-conjunctivitis"
 
 
--------------------------------------------------------------------------------------------------------------------
